Aldosterone antagonism for HFpEF

Research output: Contribution to journalArticle

3 Scopus citations


No therapy has been proven to reduce morbidity and mortality in patients with heart failure and preserved ejection fraction (HFpEF). Owing to the deleterious cardiovascular effects of aldosterone, mineralocorticoid antagonists hold promise to treat this disorder. The Aldo-DHF trial provides valuable insights into the effects of these agents in HFpEF.

Original languageEnglish (US)
Pages (from-to)244-246
Number of pages3
JournalNature Reviews Cardiology
Issue number5
StatePublished - May 2013


ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this